The International Task Force on Canine Atopic Dermatitis has published new, evidence-based guidelines for diagnosing, grading and treating Canine Atopic Dermatitis (AD).
Recently published in Veterinary Dermatology, the series of guidelines for general practitioners covers all aspects of the disease, including the recent rise in food allergy-related cases, and offers practical guidance for vets in diagnosing and grading the severity of AD.
The report also reviews the most appropriate treatment options for acute and chronic forms of the disease, and has awarded Cortavance (hydrocortisone aceponate) the best strength of evidence mark of any current treatment available.
Virbac technical director Chris Taylor MRCVS says the paper shows that Cortavance is now the benchmark for Atopic Dermatitis: "Not only do the guidelines confirm evidence of treatment success with Cortavance, but they also highlight that the skin-specific steroid spray has been shown to have no systemic effects, even when applied to one-third of the dog on a daily basis."
Chris also highlights the cost-effectiveness of Cortavance: "Some AD treatments can cost clients more than £2 per day, but with Cortavance owners are usually looking at costs of just pence per day.
"This report shows that not only is Cortavance the most effective treatment with a high safety margin, it is also surprisingly inexpensive too. And of course this should also help with compliance, particularly in uninsured animals."
The guidelines can be viewed or downloaded online free at: http://onlinelibrary.wiley.com/doi/10.1111/j.1365.3164.2010.00889.x/pdf